Abteilung Virologie Teil des Zentrums für Infektiologie
Abteilung Virologie Teil des Zentrums für Infektiologie
Kliniken & Institute … Institute Zentrum für… Abteilung Virologie … Forschung Mücksch Lab
Forschungsgruppen

Research group Mücksch

Research projects in our group focus on “HIV-1 infection and latency”

This group is located on the 3rd floor of the Center for Integrative Infectious Disease Research (CIID) at INF344 and supported by the Chica and Heinz Schaller Foundation Heidelberg.

Projects

The Mücksch lab is interested in gaining a better understanding of the interplay between HIV-1 and its host cells during HIV-1 infection and latency at the cellular and molecular level.

HIV infection remains one of the world’s most relevant infectious diseases with more than 38 million people worldwide living with HIV. Since the beginning of the HIV epidemic, more than 84 million people have been infected with HIV and about 40 million have died of HIV.

Intensive research has led to the development of antiretroviral therapy (ART), which has since been applied to control HIV infection in people living with HIV. However, despite available therapies, HIV infection still cannot be cured, resulting in a need for life-long ART. This imposes severe challenges on people living with HIV, such as limited access to ART, strict medication schedule, stigma, side-effects, and inflammation-associated co-morbidities.

The absence of a cure for HIV infection results from the formation of a latent reservoir which cannot be targeted by current therapies. HIV integrates into the host cell genome where it can persist as a latent provirus during antiretroviral treatment. Treatment interruption inevitably leads to viral rebound. With this, the latent reservoir presents the main challenge to the development of a cure for HIV infection and cure can thus only result from a detailed understanding of these processes.

The overall aim of the Mücksch lab is to study and understand the mechanisms underlying latent HIV-1 infection. Our research goals are to characterize the heterogeneity of HIV-1 latency in cell models and primary cells, investigate how HIV enters and reverses from latency, and define the viral and host factors responsible for these processes.

We believe that a process as heterogeneous and multi-factorial as HIV-1 latency can only be studied using diverse tools and models. We are applying a proviral latency reporter, which allows for rapid separation of cells harboring transcriptionally active vs. inactive proviruses. This reporter enabled us to establish exceptionally large and diverse libraries of hundreds of latently infected T cell lines. Together with human primary cell models, we are using these tools combined with molecular virology, genetics, immunology, and microscopy techniques to dissect HIV-host interactions and understand the mechanisms underlying latency establishment, maintenance, and reversal.

Through this we expect to gain a better understanding of the regulation of HIV-1 latency to get one step closer to achieving a cure for HIV.

 

  • Yang L, Van Beek M, Wang Z, Muecksch F, Canis M, Hatziioannou T, Bieniasz PD, Nussenzweig MC, Chakraborty AK (2022) Antigen presentation dynamics shape the response to emergent variants like SARS-CoV-2 Omicron strain after multiple vaccinations with wild type strain. bioRxiv https://doi.org/10.1101/2022.08.24.505127
  • Witte L, Baharani V, Schmidt F, Wang Z, Cho A, Raspe R, Guzman-Cardozo MC, Muecksch F, Gaebler C, Caskey M, Nussenzweig MC, Hatziioannou T, Bieniasz PD (2022) Epistasis lowers the genetic barrier to SARS-CoV-2 neutralizing antibody escape. bioRxiv https://doi.org/10.1101/2022.08.17.504313
  • Wang Z*, Zhou P*, Muecksch F*, Cho A*, Ben Tanfous T, Canis M, Witte L, Johnson B, Raspe R, Schmidt F, Bednarski E, Da Silva J, Ramos V, Zong S, Turroja M, Millard KG, Yao KH, Shimeliovich I, Dizon J, Kaczynska A, Jankovic M, Gazumyan A, Oliveira TY, Caskey M, Gaebler C, Bieniasz PD, Hatziioannou T, Nussenzweig MC (2022) Memory B cell responses to Omicron subvariants after SARS-CoV-2 mRNA breakthrough infection in humans. J Exp Med. 219(12) https://doi.org/10.1084/jem.20221006
  • Wang Z*, Muecksch F*, Muenn F*, Cho A*, Zong S, Raspe R, Ramos V, Johnson B, Ben Tanfous T, DaSilva J, Bednarski E, Guzman-Cardozo C, Turroja M, Millard KG, Tober-Lau P, Hillus D, Yao KH, Shimeliovich I, Dizon J, Kaczynska A, Jankovic M, Gazumyan A, Oliveira TY, Caskey M, Bieniasz PD, Hatziioannou T, Kurth F, Sander LE, Nussenzweig MC, Gaebler C (2022) Humoral immunity to SARS-CoV-2 elicited by combination COVID-19 vaccination regimens. J Exp Med. 219(10) https://doi.org/10.1084/jem.20220826
  • Wang Z*, Muecksch F*, Cho A, Gaebler C, Hoffmann HH, Ramos V, Zong S, Cipolla M, Johnson B, Schmidt F, DaSilva J, Bednarski E, Ben Tanfous T, Raspe R, Yao K, Lee YE, Chen T, Turroja M, Milard KG, Dizon J, Kaczynska A, Gazumyan A, Oliveira TY, Rice CM, Caskey M, Bieniasz PD, Hatziioannou T, Barnes CO, Nussenzweig MC (2022) Analysis of memory B cells identifies conserved neutralizing epitopes on the N-terminal domain of variant SARS-Cov-2 spike proteins. Immunity. 55(6):998-1012 e1018  https://doi.org/10.1016/j.immuni.2022.04.003
  • Schmidt F*, Muecksch F*, Weisblum Y, Da Silva J, Bednarski E, Cho A, Wang Z, Gaebler C, Caskey M, Nussenzweig MC, Hatziioannou T, Bieniasz PD (2022) Plasma Neutralization of the SARS-CoV-2 Omicron Variant. N Engl J Med. 386(6):599-601  https://doi.org/10.1056/NEJMc2119641
  • Schaefer-Babajew D*, Wang Z, Muecksch F*, Cho A*, Raspe R, Johnson B, Canis M, DaSilva J, Ramos V, Turroja M, Millard KG, Schmidt F, Dizon J, Shimelovich I, Yao KH, Oliveira TY, Gazumyan A, Gaebler C, Bieniasz PD, Hatziioannou T, Caskey M, Nussenzweig MC (2022) Antibody feedback regulation of memory B cell development in SARS-CoV-2 mRNA vaccination. medRxiv https://doi.org/10.1101/2022.08.05.22278483
  • Muecksch F*, Wise H*, Templeton K, Batchelor B, Squires M, McCance K, Jarvis L, Malloy K, Furrie E, Richardson C, MacGuire J, Godber I, Burns A, Mavin S, Zhang F, Schmidt F, Bieniasz PD, Jenks S, Hatziioannou T (2022) Longitudinal variation in SARS-CoV-2 antibody levels and emergence of viral variants: a serological analysis. Lancet Microbe. 3(7):e493-e502  https://doi.org/10.1016/S2666-5247(22)00090-8
  • Muecksch F*, Wang Z*, Cho A*, Gaebler C, Ben Tanfous T, DaSilva J, Bednarski E, Ramos V, Zong S, Johnson B, Raspe R, Schaefer-Babajew D, Shimeliovich I, Daga M, Yao KH, Schmidt F, Millard KG, Turroja M, Jankovic M, Oliveira TY, Gazumyan A, Caskey M, Hatziioannou T, Bieniasz PD, Nussenzweig MC (2022) Increased memory B cell potency and breadth after a SARS-CoV-2 mRNA boost. Nature. 607(7917):128-134  https://doi.org/10.1038/s41586-022-04778-y
  • McCance K, Wise H, Simpson J, Batchelor B, Hale H, McDonald L, Zorzoli A, Furrie E, Chopra C, Muecksch F, Hatziioannou T, Bieniasz PD, Templeton K, Jenks S (2022) Evaluation of SARS-CoV-2 antibody point of care devices in the laboratory and clinical setting. PLoS One. 17(3):e0266086  https://doi.org/10.1371/journal.pone.0266086
  • Kastenhuber ER, Mercadante M, Nilsson-Payant B, Johnson JL, Jaimes JA, Muecksch F, Weisblum Y, Bram Y, Chandar V, Whittaker GR, tenOever BR, Schwartz RE, Cantley L (2022) Coagulation factors directly cleave SARS-CoV-2 spike and enhance viral entry. Elife. 11 https://doi.org/10.7554/eLife.77444
  • Gaebler C, DaSilva J, Bednarski E, Muecksch F, Schmidt F, Weisblum Y, Millard KG, Turroja M, Cho A, Wang Z, Caskey M, Nussenzweig MC, Bieniasz PD, Hatziioannou T (2022) Severe Acute Respiratory Syndrome Coronavirus 2 Neutralization After Messenger RNA Vaccination and Variant Breakthrough Infection. Open Forum Infect Dis. 9(7):ofac227  https://doi.org/10.1093/ofid/ofac227
  • Cho A*, Muecksch F*, Wang Z*, Ben Tanfous T, DaSilva J, Raspe R, Johnson B, Bednarski E, Ramos V, Schaefer-Babajew D, Shimeliovich I, Dizon JP, Yao KH, Schmidt F, Millard KG, Turroja M, Jankovic M, Oliveira TY, Gazumyan A, Gaebler C, Caskey M, Hatziioannou T, Bieniasz PD, Nussenzweig MC (2022) Antibody evolution to SARS-CoV-2 after single-dose Ad26.COV2.S vaccine in humans. J Exp Med. 219(8) https://doi.org/10.1084/jem.20220732
  • Agudelo M, Muecksch F, Schaefer-Babajew D, Cho A, DaSilva J, Bednarski E, Ramos V, Oliveira TY, Cipolla M, Gazumyan A, Zong S, Rodrigues DAS, Lira GS, Conde L, Aguiar RS, Ferreira OC, Tanuri A, Affonso KC, Galliez RM, Castineiras T, Echevarria-Lima J, Bozza MT, Vale AM, Bieniasz PD, Hatziioannou T, Nussenzweig MC (2022) Plasma and memory antibody responses to Gamma SARS-CoV-2 provide limited cross-protection to other variants. J Exp Med. 219(9) https://doi.org/10.1084/jem.20220367
  • Xu J, Xu K, Jung S, Conte A, Lieberman J, Muecksch F, Lorenzi JCC, Park S, Schmidt F, Wang Z, Huang Y, Luo Y, Nair MS, Wang P, Schulz JE, Tessarollo L, Bylund T, Chuang GY, Olia AS, Stephens T, Teng IT, Tsybovsky Y, Zhou T, Munster V, Ho DD, Hatziioannou T, Bieniasz PD, Nussenzweig MC, Kwong PD, Casellas R (2021) Nanobodies from camelid mice and llamas neutralize SARS-CoV-2 variants. Nature. 595(7866):278-282  https://doi.org/10.1038/s41586-021-03676-z
  • Wang Z*, Schmidt F*, Weisblum Y*, Muecksch F*, Barnes CO*, Finkin S*, Schaefer-Babajew D*, Cipolla M*, Gaebler C*, Lieberman JA*, Oliveira TY, Yang Z, Abernathy ME, Huey-Tubman KE, Hurley A, Turroja M, West KA, Gordon K, Millard KG, Ramos V, Da Silva J, Xu J, Colbert RA, Patel R, Dizon J, Unson-O'Brien C, Shimeliovich I, Gazumyan A, Caskey M, Bjorkman PJ, Casellas R, Hatziioannou T, Bieniasz PD, Nussenzweig MC (2021) mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Nature. 592(7855):616-622  https://doi.org/10.1038/s41586-021-03324-6
  • Wang Z*, Muecksch F*, Schaefer-Babajew D*, Finkin S*, Viant C*, Gaebler C*, Hoffmann HH, Barnes CO, Cipolla M, Ramos V, Oliveira TY, Cho A, Schmidt F, Da Silva J, Bednarski E, Aguado L, Yee J, Daga M, Turroja M, Millard KG, Jankovic M, Gazumyan A, Zhao Z, Rice CM, Bieniasz PD, Caskey M, Hatziioannou T, Nussenzweig MC (2021) Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection. Nature. 595(7867):426-431  https://doi.org/10.1038/s41586-021-03696-9
  • Wang Z*, Lorenzi JCC*, Muecksch F*, Finkin S*, Viant C, Gaebler C, Cipolla M, Hoffmann HH, Oliveira TY, Oren DA, Ramos V, Nogueira L, Michailidis E, Robbiani DF, Gazumyan A, Rice CM, Hatziioannou T, Bieniasz PD, Caskey M, Nussenzweig MC (2021) Enhanced SARS-CoV-2 neutralization by dimeric IgA. Sci Transl Med. 13(577) https://doi.org/10.1126/scitranslmed.abf1555
  • Van Rompay KKA, Olstad KJ, Sammak RL, Dutra J, Watanabe JK, Usachenko JL, Immareddy R, Verma A, Shaan Lakshmanappa Y, Schmidt BA, Roh JW, Elizaldi SR, Allen AM, Muecksch F, Lorenzi JCC, Lockwood S, Pollard RE, Yee JL, Nham PB, Ardeshir A, Deere JD, Patterson J, Dang Q, Hatziioannou T, Bieniasz PD, Iyer SS, Hartigan-O'Connor DJ, Nussenzweig MC, Reader JR (2021) Early treatment with a combination of two potent neutralizing antibodies improves clinical outcomes and reduces virus replication and lung inflammation in SARS-CoV-2 infected macaques. PLoS Pathog. 17(7):e1009688  https://doi.org/10.1371/journal.ppat.1009688
  • Scheid JF, Barnes CO, Eraslan B, Hudak A, Keeffe JR, Cosimi LA, Brown EM, Muecksch F, Weisblum Y, Zhang S, Delorey T, Woolley AE, Ghantous F, Park SM, Phillips D, Tusi B, Huey-Tubman KE, Cohen AA, Gnanapragasam PNP, Rzasa K, Hatziioanno T, Durney MA, Gu X, Tada T, Landau NR, West AP, Jr., Rozenblatt-Rosen O, Seaman MS, Baden LR, Graham DB, Deguine J, Bieniasz PD, Regev A, Hung D, Bjorkman PJ, Xavier RJ (2021) B cell genomics behind cross-neutralization of SARS-CoV-2 variants and SARS-CoV. Cell. 184(12):3205-3221 e3224  https://doi.org/10.1016/j.cell.2021.04.032
  • Schafer A, Muecksch F, Lorenzi JCC, Leist SR, Cipolla M, Bournazos S, Schmidt F, Maison RM, Gazumyan A, Martinez DR, Baric RS, Robbiani DF, Hatziioannou T, Ravetch JV, Bieniasz PD, Bowen RA, Nussenzweig MC, Sheahan TP (2021) Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo. J Exp Med. 218(3) https://doi.org/10.1084/jem.20201993
  • Qu K, Ke Z, Zila V, Anders-Osswein M, Glass B, Mücksch F, Muller R, Schultz C, Muller B, Krausslich HG, Briggs JAG (2021) Maturation of the matrix and viral membrane of HIV-1. Science. 373(6555):700-704  https://doi.org/10.1126/science.abe6821
  • Muecksch F*, Wise H*, Batchelor B, Squires M, Semple E, Richardson C, McGuire J, Clearly S, Furrie E, Greig N, Hay G, Templeton K, Lorenzi JCC, Hatziioannou T, Jenks S, Bieniasz PD (2021) Longitudinal Serological Analysis and Neutralizing Antibody Levels in Coronavirus Disease 2019 Convalescent Patients. Journal of Infectious Diseases. 223(3):389-398  https://doi.org/10.1093/infdis/jiaa659
  • Muecksch F*, Weisblum Y*, Barnes CO*, Schmidt F*, Schaefer-Babajew D, Wang Z, JC CL, Flyak AI, DeLaitsch AT, Huey-Tubman KE, Hou S, Schiffer CA, Gaebler C, Da Silva J, Poston D, Finkin S, Cho A, Cipolla M, Oliveira TY, Millard KG, Ramos V, Gazumyan A, Rutkowska M, Caskey M, Nussenzweig MC, Bjorkman PJ, Hatziioannou T, Bieniasz PD (2021) Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations. Immunity. 54(8):1853-1868 e1857  https://doi.org/10.1016/j.immuni.2021.07.008
  • McDonald L, Wise H, Muecksch F, Poston D, Mavin S, Templeton K, Furrie E, Richardson C, McGuire J, Jarvis L, Malloy K, McAuley A, Palmateer N, Dickson E, Hatziioannou T, Bieniasz P, Jenks S (2021) Comparison of SARS-CoV-2 serological assays for use in epidemiological surveillance in Scotland. J Clin Virol Plus. 1(3):100028  https://doi.org/10.1016/j.jcvp.2021.100028
  • Jette CA, Cohen AA, Gnanapragasam PNP, Muecksch F, Lee YE, Huey-Tubman KE, Schmidt F, Hatziioannou T, Bieniasz PD, Nussenzweig MC, West AP, Jr., Keeffe JR, Bjorkman PJ, Barnes CO (2021) Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodies. Cell Rep. 37(12):110188  https://doi.org/10.1016/j.celrep.2021.110188
  • Hacisuleyman E, Hale C, Saito Y, Blachere NE, Bergh M, Conlon EG, Schaefer-Babajew DJ, DaSilva J, Muecksch F, Gaebler C, Lifton R, Nussenzweig MC, Hatziioannou T, Bieniasz PD, Darnell RB (2021) Vaccine Breakthrough Infections with SARS-CoV-2 Variants. N Engl J Med. 384(23):2212-2218  https://doi.org/10.1056/NEJMoa2105000
  • Greaney AJ, Starr TN, Barnes CO, Weisblum Y, Schmidt F, Caskey M, Gaebler C, Cho A, Agudelo M, Finkin S, Wang Z, Poston D, Muecksch F, Hatziioannou T, Bieniasz PD, Robbiani DF, Nussenzweig MC, Bjorkman PJ, Bloom JD (2021) Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies. Nat Commun. 12(1):4196  https://doi.org/10.1038/s41467-021-24435-8
  • Gaebler C*, Wang Z*, Lorenzi JCC*, Muecksch F*, Finkin S*, Tokuyama M*, Cho A*, Jankovic M*, Schaefer-Babajew D*, Oliveira TY*, Cipolla M*, Viant C, Barnes CO, Bram Y, Breton G, Hagglof T, Mendoza P, Hurley A, Turroja M, Gordon K, Millard KG, Ramos V, Schmidt F, Weisblum Y, Jha D, Tankelevich M, Martinez-Delgado G, Yee J, Patel R, Dizon J, Unson-O'Brien C, Shimeliovich I, Robbiani DF, Zhao Z, Gazumyan A, Schwartz RE, Hatziioannou T, Bjorkman PJ, Mehandru S, Bieniasz PD, Caskey M, Nussenzweig MC (2021) Evolution of antibody immunity to SARS-CoV-2. Nature. 591(7851):639-644  https://doi.org/10.1038/s41586-021-03207-w
  • Freedenberg AT, Pan CH, Diehl WE, Romeiser JL, Hwang GR, Leiton CV, Muecksch F, Shroyer KR, Bennett-Guerrero E (2021) Neutralizing activity to SARS-CoV-2 of convalescent and control plasma used in a randomized controlled trial. Transfusion. 61(5):1363-1369  https://doi.org/10.1111/trf.16283
  • De Gasparo R, Pedotti M, Simonelli L, Nickl P, Muecksch F, Cassaniti I, Percivalle E, Lorenzi JCC, Mazzola F, Magri D, Michalcikova T, Haviernik J, Honig V, Mrazkova B, Polakova N, Fortova A, Tureckova J, Iatsiuk V, Di Girolamo S, Palus M, Zudova D, Bednar P, Bukova I, Bianchini F, Mehn D, Nencka R, Strakova P, Pavlis O, Rozman J, Gioria S, Sammartino JC, Giardina F, Gaiarsa S, Pan-Hammarstrom Q, Barnes CO, Bjorkman PJ, Calzolai L, Piralla A, Baldanti F, Nussenzweig MC, Bieniasz PD, Hatziioannou T, Prochazka J, Sedlacek R, Robbiani DF, Ruzek D, Varani L (2021) Bispecific IgG neutralizes SARS-CoV-2 variants and prevents escape in mice. Nature. 593(7859):424-428  https://doi.org/10.1038/s41586-021-03461-y
  • Cho A*, Muecksch F*, Schaefer-Babajew D*, Wang Z*, Finkin S*, Gaebler C, Ramos V, Cipolla M, Mendoza P, Agudelo M, Bednarski E, DaSilva J, Shimeliovich I, Dizon J, Daga M, Millard KG, Turroja M, Schmidt F, Zhang F, Tanfous TB, Jankovic M, Oliveria TY, Gazumyan A, Caskey M, Bieniasz PD, Hatziioannou T, Nussenzweig MC (2021) Anti-SARS-CoV-2 receptor-binding domain antibody evolution after mRNA vaccination. Nature. 600(7889):517-522  https://doi.org/10.1038/s41586-021-04060-7
  • Bou-Nader C*, Muecksch F*, Brown JB, Gordon JM, York A, Peng C, Ghirlando R, Summers MF, Bieniasz PD, Zhang J (2021) HIV-1 matrix-tRNA complex structure reveals basis for host control of Gag localization. Cell Host Microbe. 29(9):1421-1436 e1427  https://doi.org/10.1016/j.chom.2021.07.006
  • Weisblum Y*, Schmidt F*, Zhang F, DaSilva J, Poston D, Lorenzi JC, Muecksch F, Rutkowska M, Hoffmann HH, Michailidis E, Gaebler C, Agudelo M, Cho A, Wang Z, Gazumyan A, Cipolla M, Luchsinger L, Hillyer CD, Caskey M, Robbiani DF, Rice CM, Nussenzweig MC, Hatziioannou T, Bieniasz PD (2020) Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. Elife. 9 https://doi.org/10.7554/eLife.61312
  • Schmidt F*, Weisblum Y*, Muecksch F*, Hoffmann HH, Michailidis E, Lorenzi JCC, Mendoza P, Rutkowska M, Bednarski E, Gaebler C, Agudelo M, Cho A, Wang ZJ, Gazumyan A, Cipolla M, Caskey M, Robbiani DF, Nussenzweig MC, Rice CM, Hatziioannou T, Bieniasz PD (2020) Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses. Journal of Experimental Medicine. 217(11) https://doi.org/ARTN e2020118110.1084/jem.20201181
  • Robbiani DF*, Gaebler C*, Muecksch F*, Lorenzi JCC*, Wang Z*, Cho A*, Agudelo M*, Barnes CO*, Gazumyan A*, Finkin S*, Hagglof T*, Oliveira TY*, Viant C*, Hurley A, Hoffmann HH, Millard KG, Kost RG, Cipolla M, Gordon K, Bianchini F, Chen ST, Ramos V, Patel R, Dizon J, Shimeliovich I, Mendoza P, Hartweger H, Nogueira L, Pack M, Horowitz J, Schmidt F, Weisblum Y, Michailidis E, Ashbrook AW, Waltari E, Pak JE, Huey-Tubman KE, Koranda N, Hoffman PR, West AP, Jr., Rice CM, Hatziioannou T, Bjorkman PJ, Bieniasz PD, Caskey M, Nussenzweig MC (2020) Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature. 584(7821):437-442  https://doi.org/10.1038/s41586-020-2456-9
  • Luchsinger LL, Ransegnola BP, Jin DK, Muecksch F, Weisblum Y, Bao W, George PJ, Rodriguez M, Tricoche N, Schmidt F, Gao C, Jawahar S, Pal M, Schnall E, Zhang H, Strauss D, Yazdanbakhsh K, Hillyer CD, Bieniasz PD, Hatziioannou T (2020) Serological Assays Estimate Highly Variable SARS-CoV-2 Neutralizing Antibody Activity in Recovered COVID-19 Patients. J Clin Microbiol. 58(12) https://doi.org/10.1128/JCM.02005-20
  • Barnes CO, West AP, Jr., Huey-Tubman KE, Hoffmann MAG, Sharaf NG, Hoffman PR, Koranda N, Gristick HB, Gaebler C, Muecksch F, Lorenzi JCC, Finkin S, Hagglof T, Hurley A, Millard KG, Weisblum Y, Schmidt F, Hatziioannou T, Bieniasz PD, Caskey M, Robbiani DF, Nussenzweig MC, Bjorkman PJ (2020) Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies. Cell. 182(4):828-842 e816  https://doi.org/10.1016/j.cell.2020.06.025
  • Baisa G, Rancour D, Mansfield K, Burns M, Martin L, Cunha D, Fischer J, Muecksch F, Hatziioannou T, Bieniasz P, Schomburg F, Luke K (2020) A recombinant protein SARS-CoV-2 candidate vaccine elicits high-titer neutralizing antibodies in macaques. bioRxiv https://doi.org/10.1101/2020.12.20.422693
  • Mücksch F*, Citir M*, Luchtenborg C, Glass B, Traynor-Kaplan A, Schultz C, Brugger B, Krausslich HG (2019) Quantification of phosphoinositides reveals strong enrichment of PIP2 in HIV-1 compared to producer cell membranes. Sci Rep. 9(1):17661  https://doi.org/10.1038/s41598-019-53939-z
  • Mücksch F, Laketa V, Muller B, Schultz C, Krausslich HG (2017) Synchronized HIV assembly by tunable PIP2 changes reveals PIP2 requirement for stable Gag anchoring. Elife. 6 https://doi.org/10.7554/eLife.25287
  • Zink S, Grosse L, Freikamp A, Banfer S, Müksch F, Jacob R (2012) Tubulin detyrosination promotes monolayer formation and apical trafficking in epithelial cells. J Cell Sci. 125(Pt 24):5998-6008  https://doi.org/10.1242/jcs.109470
  • Ziege M, Hennige-Schulz C, Muecksch F, Bierbach D, Tiedemann R, Streit B, Plath M (2012) A comparison of two methods to assess audience-induced changes in male mate choice. Current Zoology. 58(1):84-94  https://doi.org/DOI 10.1093/czoolo/58.1.84
  • Bierbach D, Girndt A, Hamfler S, Klein M, Mücksch F, Penshorn M, Schwinn M, Zimmer C, Schlupp I, Streit B, Plath M (2011) Male fish use prior knowledge about rivals to adjust their mate choice. Biol Lett. 7(3):349-351  https://doi.org/10.1098/rsbl.2010.0982

 

 

 

Dr. Frauke Mücksch, Principal Investigator
Frauke.Muecksch(at)med.uni-heidelberg.de
CIID Room 301, Phone: +49 6221 56-35643

Jannik Löhr, technician
mail
CIID Room 321, Phone: +49 6221 56-1326

Luca Menges, PhD student
mail
CIID Room 321, Phone: +49 6221 56-1326

Forschungsgruppen

Group Leader

Portrait von Frauke Mücksch
Frauke Mücksch